(19)
(11)EP 3 101 133 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
20.05.2020 Bulletin 2020/21

(21)Application number: 15742771.7

(22)Date of filing:  29.01.2015
(51)Int. Cl.: 
C12N 15/113  (2010.01)
A61P 35/02  (2006.01)
A61K 48/00  (2006.01)
(86)International application number:
PCT/CN2015/071857
(87)International publication number:
WO 2015/113511 (06.08.2015 Gazette  2015/31)

(54)

SIRNA IN TANDEM EXPRESSION AND USES THEREOF IN TREATING CHRONIC LYMPHOCYTIC LEUKEMIA

SIRNA IN TANDEM-EXPRESSION UND VERWENDUNGEN DAVON BEI DER BEHANDLUNG VON CHRONISCHER LYMPHOZYTISCHER LEUKÄMIE

EXPRESSION EN TANDEM D'ARNSI ET SES UTILISATIONS DANS LE TRAITEMENT DE LA LEUCÉMIE LYMPHOÏDE CHRONIQUE


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 29.01.2014 CN 201410043517

(43)Date of publication of application:
07.12.2016 Bulletin 2016/49

(73)Proprietor: Jiangsu Micromedmark Biotech Co., Ltd.
Taizhou, Jiangsu 225300 (CN)

(72)Inventors:
  • ZHANG, Chenyu
    Beijing 100006 (CN)
  • ZENG, Ke
    Beijing 100006 (CN)
  • GU, Hongwei
    Taizhou Jiangsu 225300 (CN)
  • WANG, Xueliang
    Taizhou Jiangsu 225300 (CN)

(74)Representative: Lavoix 
Bayerstrasse 83
80335 München
80335 München (DE)


(56)References cited: : 
WO-A1-2015/026934
WO-A2-2005/069987
CN-A- 101 684 478
WO-A2-2004/013310
WO-A2-2007/121347
CN-A- 102 154 290
  
  • K.V. GLEIXNER ET AL.: "KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib", BLOOD, vol. 118, no. 7, 16 June 2011 (2011-06-16) , pages 1885-1898, XP055411858, US ISSN: 0006-4971, DOI: 10.1182/blood-2010-06-289959 -& Gleixner K.V. et al.: Online data supplement - KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib , 16 June 2011 (2011-06-16), XP055411934, Retrieved from the Internet: URL:http://www.bloodjournal.org/content/bl oodjournal/suppl/2011/05/24/blood-2010-06- 289959.DC1/Document1.pdf?sso-checked=true [retrieved on 2017-10-02]
  • M. MACPARTLIN ET AL.: "Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells", LEUKEMIA, vol. 22, no. 7, 12 June 2008 (2008-06-12), pages 1354-1360, XP055411872, US ISSN: 0887-6924, DOI: 10.1038/leu.2008.126
  • T. ORMSBY ET AL.: "Btk is a positive regulator in the TREM-1/DAP12 signaling pathway", BLOOD, vol. 118, no. 4, 28 July 2011 (2011-07-28) , pages 936-945, XP055411876, US ISSN: 0006-4971, DOI: 10.1182/blood-2010-11-317016 -& Tereza Ormsby et al.: "Online data supplement - Generation of mouse BMDCs Mouse BMDCs were differentiated from BM cells isolated from", , 9 June 2011 (2011-06-09), XP055411935, Retrieved from the Internet: URL:http://www.bloodjournal.org/highwire/f ilestream/312588/field_highwire_adjunct_fi les/0/Document1.pdf [retrieved on 2017-10-02]
  • Rushworth Stuart A. et al.: "Myeloid Neoplasia - Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia", Blood, vol. 123, no. 8 4 December 2013 (2013-12-04), pages 1229-1238, XP55278272, DOI: 10.1182/blood-2013-06- Retrieved from the Internet: URL:http://www.bloodjournal.org/content/bl oodjournal/123/8/1229.full.pdf [retrieved on 2016-06-07] -& Stuart Rushworth: "Number", , 4 December 2013 (2013-12-04), XP055411938, Retrieved from the Internet: URL:http://www.bloodjournal.org/content/bl oodjournal/suppl/2013/12/04/blood-2013-06- 511154.DC1/blood-2013-06-511154-1.pdf [retrieved on 2017-10-02]
  • J.A. WOYACH et al.: "Lymphoid Neoplasia - Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)", BLOOD, vol. 123, no. 8 5 December 2013 (2013-12-05), XP55411848, DOI: 10.1182/blood-2013-07- Retrieved from the Internet: URL:http://www.bloodjournal.org/content/12 3/8/1207.full.pdf [retrieved on 2017-10-02] -& Jennifer Woyach: "Supplemental Figure 1: Viability of CLL cells after transfection with BTK or", , 5 December 2013 (2013-12-05), XP055411940, Retrieved from the Internet: URL:http://www.bloodjournal.org/content/bl oodjournal/suppl/2013/12/05/blood-2013-07- 515361.DC1/blood-2013-07-515361-1.pdf [retrieved on 2017-10-02]
  • HEINONEN JUHANA E. ET AL.: "Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA)", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 527, no. 1, 2002, pages 274-278, XP085069699, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(02)03206-4
  • JESSICA M. LINDVALL ET AL.: "Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling", IMMUNOLOGICAL REVIEWS, vol. 203, no. 1, 1 February 2005 (2005-02-01), pages 200-215, XP055411943, US ISSN: 0105-2896, DOI: 10.1111/j.0105-2896.2005.00225.x
  • K.V. GLEIXNER ET AL.: "Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, vol. 98, no. 9, 28 March 2013 (2013-03-28) , pages 1450-1457, XP055411945, IT ISSN: 0390-6078, DOI: 10.3324/haematol.2012.079202 -& Karoline Gleixner: "Supplementary Data I. Supplementary Methods", , 28 March 2013 (2013-03-28), XP055411948, Retrieved from the Internet: URL:http://www.haematologica.org/content/h aematol/suppl/2013/09/05/haematol.2012.079 202.DC2/2012.079202.Gleixner_suppl.pdf [retrieved on 2017-10-02]
  • "TRCN0000023691", Extract from Dharmacon (formerly Open Biosystems) catalogue , XP055412150, Retrieved from the Internet: URL:http://dharmacon.gelifesciences.com/se arch/?term=TRCN0000023691 [retrieved on 2017-10-03]
  
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description

Technical Field



[0001] The present application pertains to the medical field, more particularly, discloses a method to tandem-express BTK-specific siRNAs, tandem-expressing siRNAs and the use thereof in the treatment of chronic lymphocytic leukemia.

Background art



[0002] Chronic lymphocytic leukemia, CLL in short, is a disease of abnormal mature B lymphocyte proliferation with slow progression.

[0003] In over a half of CLL cases exist the homozygosity or heterozygosity loss of 13q14, one of the most common chromosome abnormality of CLL, which features the abnormal proliferation and storage of lymphocytes, accompanied by low immune function. CLL is mostly seen with middle-aged or old people, of whom 90% are over 50, and more liable are the males. The onset of CLL is concealed, and the clinical features are various, inert or invasive. The patients can expect a survival time of 1 to over 15 years. And the pathogenesis of CLL is not quite clear yet.

[0004] Presently the knowledge on the prognosis of CLL is limited, so that the treatment measures cannot be adopted as that is with acute leukemia, according to the prognosis risk of patients. The expected survival time of patients even with the worst prognosis can be years.

[0005] The factors to be considered in treatment include disease progression, clinical symptoms, tumor load, age, complications, adverse prognostic factors and effect of treatment on survival time, and etc. No effective treatment measures against CLL exist but the hemopoietic stem cell transplant. A typical treatment plan of CLL in hospitals mainly adopt chemotherapy, radiotherapy, interferon therapy and marrow transplant, and etc., but no ideal treatment effect can be realized, and the natural process of the disease cannot be altered.

[0006] Gleixner et al. (Blood, 2011, vol. 118, no. 7, 1885-1898) has disclosed that Lyn and Btk are phosphorylated in a KIT-independent manner in neoplastic mast cells (MCs) in advanced SM (Systemic Mastocytosis) and in the MC leukemia cell line HMC-1. Lyn and Btk activation was not only detected in KIT D816V-positive HMC-1.2 cells, but also in the KIT D816V-negative HMC-1.1 subclone. Moreover, KIT D816V did not induce Lyn/Btk activation in Ba/F3 cells, and deactivation of KIT D816V by midostaurin did not alter Lyn/Btk activation. siRNAs against Btk and Lyn were found to block survival in neoplastic MCs and to cooperate with midostaurin in producing growth inhibition. Growth inhibitory effects were also obtained with 2 targeted drugs, dasatinib which blocks KIT, Lyn, and Btk activation in MCs, and bosutinib, a drug that deactivates Lyn and Btk without blocking KIT activity. Together, KIT-independent signaling via Lyn/Btk contributes to growth of neoplastic MCs in advanced SM. Dasatinib and bosutinib disrupt Lyn/Btk-driven oncogenic signaling in neoplastic MC, which may have clinical implications and explain synergistic drug interactions.

[0007] MacPartlin et al. (Leukemia, 2008, vol. 22, no. 7, 1354-1360) has disclosed that BTK has been implicated in Bcr-Abl-mediated 8-cell transformation and resistance to imatinib, implying that inhibiting BTK may be therapeutically beneficial. In this article, it was found that proliferation and viability were unaffected by inhibition of BTK with reversible (PC-005) and irreversible (PCI-31523) small molecule inhibitors, and BTK inhibition did not affect the ability of BcrAbl to transform primary murine hematopoietic cells in colony forming and B-cell transformation assays. Collectively this data argues against a critical role for BTK in Bcr-Abl-mediated leukemogenesis.

[0008] Ormsby et al. (Blood, 2011, vol. 118, no. 4, 936-945) demonstrated that Bruton tyrosine kinase (Btk), a member of the Tee kinases, becomes phosphorylated upon TREM-1 triggering. In U937-derived cell lines, in which expression of Btk was diminished by shRNA-mediated knockdown, phosphorylation of Erk1/2 and PLCγ1 and Ca2+ mobilization were reduced after TREM-1 stimulation. Importantly, TREM-1-induced production of the pro-inflammatory cytokines, TNF-α and IL-8, and up-regulation of activation/differentiation cell surface markers were impaired in Btk knockdown cells. Similar results were obtained upon TREM-1 stimulation of BMDCs of Btk-/- mice. The analysis of cells containing Btk mutants revealed that intact membrane localization and a functional kinase domain were required for TREM-1-mediated signaling. Finally, after TREM-1 engagement, TNF-α production by PBMCs was reduced in the majority of patients suffering from X-linked agammaglobulinemia (XLA), a rare hereditary disease caused by mutations in the BTK gene.

[0009] Rushworth et al. (Blood, 2013, vol. 123, no. 8, 1229-1238) has disclosed that inhibition of Bruton's tyrosine kinase is as effective in vitro against AML as chronic lymphocytic leukemia. lbrutinib shows activity in AML (Acute Myeloid Leukemia) because Bruton's tyrosine kinase is constitutively active.

[0010] Woyach et al. (Blood, 2013, vol. 123, no. 8, online data supplement) has disclosed that kinase-functional BTK is important in the development and expansion of CLL. Both targeted genetic inactivation of BTK and inhibition of BTK by ibrutinib inhibit the development of CLL in the TCL1 mouse model.

[0011] Heinonen et al. (2002, FEBS Letters, vol. 527, no. 1, 274-278) has demonstrated that human Btk protein can transiently be depleted using double-stranded short RNA interference oligonucleotides. The induction of histamine release, a pro-inflammatory mediator, in RBL-2H3 mast cells was reduced by 20-25% upon Btk down regulation.

[0012] Lindvall et al. (Immunological reviews, 2005, vol. 203, no. 1, 200-215) has demonstrated that for the R28C-missense mutant, there is no biologically relevant residual activity or any dominant negative effect versus other proteins.

[0013] Gleixner et al. (Haematologica, 2013, vol. 98, no. 9, 1450-1457) has disclosed that ponatinib synergizes with the Btk-targeting drug dasatinib to produce growth inhibition in HMC-1 cells.

[0014] WO2005/069987 discloses a method for amplifying expression of double-stranded RNA in a cell, comprising introducing a plurality of expression cassettes encoding the double-stranded RNA, preferably together as a single unit.

[0015] Therefore, it is an urgent need in the field to develop novel methods and drugs for the effective cure of CLL.

Content of the invention



[0016] The present invention is defined in the claims.

[0017] The present application discloses a method for the treatment of CLL and the related drugs.

[0018] In the first aspect of the present application, is disclosed a reconstructed nuclein sequence to inhibit Bruton's agammaglobulinemia tyrosine kinase (BTK), of which the structure is shown as Formula V:

        A-(B-L-)p-Z     (Formula V)



[0019] In which,
A represents a random sequence of the 5' end (the length thereof is preferably 0-50bp, more preferably 0-20bp, and most preferably 0-10bp);
B represents the same or different siRNA sequences that specifically inhibit BTK, or the precursor RNA sequences that are used to produce the said siRNA sequences;
L represents random interval sequences (the length thereof is preferably 0-50bp, more preferably 0-20bp, and most preferably 0-10bp);
p is a positive integer amongst 1, 2, 3, 4 or 5;
Z represents a random sequence of the 5' end (the length thereof is preferably 0-50bp, more preferably 0-20bp, and most preferably 0-10bp);

[0020] In another preferred example, the said nucleotide sequence includes DNA or RNA sequences.

[0021] In another preferred example disclosed herein, the said B is a siRNA, of which the sequence is chosen from SEQ ID NO.: 1, 2 or 3, or a precursor RNA that is to produce the said siRNA.

[0022] In another preferred example, the said reconstructed nuclein sequence that inhibits BTK is one or several active ingredients selected from the following group:
  1. (a) BTK inhibiting-siRNAs, of which the said siRNA sequences include siRNA sequences as said in SEQ ID NO.: 1-3;
  2. (b) Precursor RNAs, which can be processed in the host into the BTK inhibiting-siRNAs as said in (a);
  3. (c) Polynucleotides, which can be transcribed in the host into the precursor RNAs as said in (b), and then processed into the siRNAs as said in (a);
  4. (d) Expression vectors, which contain the BTK inhibiting-siRNAs as said in (a), or the precursor RNAs as said in (b), or the polynucleotides as said in (c), and in the said Formula V, A and Z are connected, forming a circular shape.


[0023] In another preferred example, the said nucleotide sequence is a nucleotide sequence that co-expresses 2 or several types of siRNAs, which are the same or different.

[0024] In another preferred example, the said "reconstructed" includes the artificially synthesized.

[0025] In another preferred example, the said primer RNA can be processed in the host (for example, mammals, including humans) into the siRNA as said in (a).

[0026] In the second aspect of the present application, is disclosed a pharmaceutical composition that comprises of a pharmaceutically acceptable carrier and one or several active ingredients with effective dose and selected from the following group:
  1. (a) BTK inhibiting-siRNAs, of which the said siRNA sequences include siRNA sequences as said in SEQ ID NO.: 1-3;
  2. (b) Precursor RNAs, which can be processed in the host into the BTK inhibiting-siRNAs as said in (a);
  3. (c) Polynucleotides, which can be transcribed in the host into the precursor RNAs as said in (b), and then processed into the siRNAs as said in (a);
  4. (d) Expression vectors, which contain the BTK inhibiting-siRNAs as said in (a), or the precursor RNAs as said in (b), or the polynucleotides as said in (c); and
  5. (e) Agonists of the siRNAs as said in (a).


[0027] In another preferred example, the polynucleotides said in (c) co-express the said siRNAs that are the same or different.

[0028] In another preferred example, the said siRNAs in (a) include forms with or without modification.

[0029] In another preferred example, the said forms with modification include one or several forms selected from the following group: glycosylation modification of nucleotides, modification on the connection amongst nucleotides, cholesterol modification, locked nucleotide modification, peptide modification, lipid modification, halogen modification, alkyl modification and nuclein modification.

[0030] In another preferred example, the said glycosylation modification of nucleotides includes glycosylation modification of 2-O-methyl, 2-O-methylethyl, 2-O-alkyl, 2-fluoro, and glycoconjugate modification, locked nucleotide modification; and/or
the said modification on the connection amongst nucleotides includes thiophosphoric acid modification and phosphoric acid alkylation modification.

[0031] In another preferred example, the said modification form contains the monomer or the polymer of the compound with the structure as shown in Formula I:

        (X)n-(Y)m     Formula I



[0032] In Formula I:
Every X represents the said siRNA in (a);
Every Y represents respectively modifications that promote the administration stability of siRNAs;
Y is connected at the left side, right side or middle of X;
n is a positive integer in 1-100 (more preferably 1-20) (more preferably n is 1, 2, 3, 4 or 5) ;
m is a positive integer in 1-1000 (more preferably 1-200) ;
Every "-" represents a connector, chemical bond, or covalent bond.

[0033] In another preferred example, the said connector is a nucleotide sequence with a length of 1-10 bases.

[0034] In another preferred example, the said Y includes (but is not limited to) cholesterol, steroid, sterol, alcohol, organic acid, aliphatic acid, ester, monosaccharide, polysaccharide, amino acid, polypeptide, mononucleotide, polynucleotide.

[0035] In another preferred example, the sequence of the said polynucleotide in (c) is as shown in SEQ ID NO.: 7.



[0036] In which, the sequence of SEQ ID NO.: 7 is a polynucleotide sequence with tandem-connected BTK-1-2-3, in which:
The sequence of the polynucleotide relating to BTK-1 (i.e., DNA sequence that encodes the precursor RNA) is:



[0037] The sequence of the polynucleotide relating to BTK-2 (i.e., DNA sequence that encodes the precursor RNA) is:



[0038] The sequence of the polynucleotide relating to BTK-3 (i.e., DNA sequence that encodes the precursor RNA) is:



[0039] And the siRNA sequences of the 3 BTKs are as follows:

BTK-1: UUCACUGGACUCUUCACCUCU(SEQ ID NO.: 1);

BTK-2: UUAGCAGUUGCUCAGCCUGAC(SEQ ID NO.: 2);

BTK-3: AACAGUUUCGAGCUGCCAGGU(SEQ ID NO.: 3).



[0040] In another preferred example, the polynucleotide said in (c) comprises one or several structure units as shown in Formula II:

        Seqforward-X-Seqbackward     Formula II



[0041] In Formula II,
Seqforward is a nucleotide sequence that can be processed in the host into the said microRNA;
Seqbackward is a nucleotide sequence that is substantially or completely complementary with the Seqforward;
X is an interval sequence between the Seqforward and Seqbackward, and is not complementary therewith;

[0042] Being transferred into the host cell, the structure shown in Formula II will form a secondary structure as shown in Formula III:



[0043] In Formula III, the Seqforward and Seqbackward and X are defined as above;
∥ represents the base complementary relationship between the Seqforward and Seqbackward;
And the Seqforwards in each construct unit can be the same or different.

[0044] In another preferred example, the expression vector said in (d) includes: viral vector or non-viral vector.

[0045] In another preferred example disclosed herein, the agonist of BTK-inhibiting siRNAs is selected from the following group: substance that promotes the expression of BTK-inhibiting siRNAs, substance that promotes the activity of BTK-inhibiting siRNA.

[0046] In the third aspect of the present application, is disclosed the use of an active ingredient, which is selected from the following group:
  1. (a) BTK inhibiting-siRNAs, of which the said siRNA sequences include siRNA sequences as said in SEQ ID NO.: 1-3;
  2. (b) Precursor RNAs, which can be processed in the host into the BTK inhibiting-siRNAs as said in (a);
  3. (c) Polynucleotides, which can be transcribed in the host into the precursor RNAs as said in (b), and then processed into the siRNAs as said in (a);
  4. (d) Expression vectors, which contain the BTK inhibiting-siRNAs as said in (a), or the precursor RNAs as said in (b), or the polynucleotides as said in (c); and
  5. (e) Agonists of the siRNAs as said in (a).


[0047] The said active ingredient is used to prepare drugs for the inhibition of BTKs, or the prevention or treatment of CLL.

[0048] In another preferred example, the said active ingredient is the polynucleotide as said in (c), and the said polynucleotides co-express the said siRNAs that are the same or different.

[0049] In another preferred example, the said polynucleotides co-express the siRNAs shown by SEQ ID NO.: 1, 2 and 3.

[0050] In the fourth aspect of the present application, is disclosed a method for the prevention or treatment of CLL, administering the subject in need with safe and effective dose the medical composition as said in the second aspect, and the re-constructed, BTK-inhibiting nucleotide sequence as said in the first aspect of the present application.

[0051] It shall be understood that, within the scope of the present invention, the aforesaid technical features and the technical features as specified in the following content (e.g., in the examples) can be combined with each other, so as to form new or more preferable technical strategy. For the economy of words, the combinations will not be listed herein one by one.

Brief description of the drawings



[0052] 

Figure 1 shows the construct of the co-expressing siRNA in one example of the present invention.

Figure 2 shows the effect of the siRNA on the expression of BTK mRNA in one example of the present invention.

Figure 3 shows that the BTK expression in the CLL patients is significantly higher than that of the normal persons, in which "1" represents the normal persons, and "2" represents the CLL patients.

Figure 4 shows that, being proved with the Western blotting method, the siRNA of the present invention can inhibit the expression of BTK, in which "1" represents the control, "2" represents P1, "3" represents P2, "4" represents P3, and "5" represents P1-2-3.

Figure 5 shows with the Western blotting method the effect of BTK siRNA on BTK protein.

Figure 6 shows the quantitative analysis results of BTK siRNA on BTK protein.

Figure 7 shows the content of BTK-1 after the transfection of P1 plasmid, in which "plasmid nc" represents being transfected with blank expression vector as the negative control; "plasmid-1" represents that the transfected P1 plasmid can express BTK-1, "plasmid-1-2-3" represents that the transfected P1-2-3 plasmid can express BTK 1-2-3.

Figure 8 shows the content of BTK-2 after the transfection of P2 plasmid, in which "plasmid nc" represents being transfected with blank expression vector as the negative control; "plasmid-2" represents that the transfected P2 plasmid can express BTK-2, "plasmid-1-2-3" represents that the transfected P1-2-3 plasmid can express BTK 1-2-3.

Figure 9 shows the content of BTK-3 after the transfection of P3 plasmid, in which "plasmid nc" represents being transfected with blank expression vector as the negative control; "plasmid-3" represents that the transfected P3 plasmid can express BTK-3, "plasmid-1-2-3" represents that the transfected P1-2-3 plasmid can express BTK 1-2-3.

Figure 10 shows the content of BTK mRNA in the B lymphocytes after the transfection of P1, P2, P3, P1-2-3 plasmids.



[0053] In each figure, "control" represents the control, "mock" represents the blank control; "nc" represents being transfected with blank expression vectors (the negative control); "plasmid-1" represents that the transfected P1 plasmid can express BTK-1, "plasmid-2" represents that the transfected P2 plasmid can express BTK-2, "plasmid-3" represents that the transfected P3 plasmid can express BTK-3, and "plasmid-1-2-3" represents that the transfected P1-2-3 plasmid can express BTK1-2-3.

Particular embodiments



[0054] The inventors discover through wide and in-depth researches and massive screening of nucleotide sequences that certain siRNAs possess rather strong BTK inhibition ability, and when they are tandem-expressed, the inhibition effect is even stronger. Therefore, the expression and activity of BTK can be effectively inhibited through importing the siRNAs that specifically inhibit BTK; thereby CLL can be prevented and treated. The present invention is completed on this basis.

Active ingredients disclosed herein



[0055] As used herein, the "active ingredients disclosed herein" refer to one or more kinds of active ingredients selected from the following group (including the combination thereof):
  1. (a) BTK-inhibiting siRNAs, the sequence of which comprises any of the siRNA sequences as said in SEQ ID NO.: 1-3 (including the combination thereof);
  2. (b) Precursor RNAs, which can be processed in the host into the BTK inhibiting-siRNAs as said in (a);
  3. (c) Polynucleotides, which can be transcribed in the host into the precursor RNAs as said in (b), and then processed into the siRNAs as said in (a);
  4. (d) Expression vectors, which contain the BTK inhibiting-siRNAs as said in (a), or the precursor RNAs as said in (b), or the polynucleotides as said in (c); and
  5. (e) Agonists of the siRNAs as said in (a).

SiRNAs and precursors thereof



[0056] The present invention provides a type of siRNA for the treatment of CLL. As used herein, the said "siRNA" refers to a type of RNA molecules, which can be processed with the transcription product that can form the siRNA precursors. Mature siRNAs usually comprise 18-26 nucleotides (nt) (more particularly, 19-22nt), not excluding other numbers of nucleotides. The siRNAs can usually be detected with Northern blotting.

[0057] As used herein, "isolated" refers to that a substance is isolated from its original environment (if the substance is a natural substance, its original environment is the natural environment). For example, the polynucleotides and polypeptides in a living cell are not isolated and purified in the natural state, but the same polynucleotides and polypeptides are isolated and purified when they are isolated from the other substances co-existing in the natural state.

[0058] It shall be notified that siRNAs are usually produced through simulating the production mechanism of miRNAs. The siRNAs can be processed from precursor RNAs (pre-RNAs). The said pre-RNAs can fold into a stable stem-loop (hairpin) structure, of which the length is usually within 50-100bp. The two sides of the stem part of the said stem-loop structure comprise two sequences that are substantially complementary. The said pre-RNA can be natural occurring or artificially synthesized.

[0059] The pre-RNA can be cut to generate siRNA. And said siRNA may be substantially complementary to at least a portion of the sequence of the mRNA encoding the gene. As used herein, "substantially complementary" means that the nucleotide sequence is sufficiently complementary and can act upon each other in a predictable manner, e.g., forming a secondary structure (such as a stem-loop structure). Generally, at least 70% of nucleotides in two "substantially complementary" nucleotide sequences are complementary; preferably, at least 80% of nucleotides are complementary; more preferably, at least 90% of nucleotides are complementary; and further preferably, at least 95% of nucleotides are complementary, e.g., 98%, 99% or 100%. Generally, there are at most 40 non-matched nucleotides between two sufficiently complementary molecules; preferably, there are at most 30 non-matched nucleotides; more preferably, there are at most 20 non-matched nucleotides; and further preferably, there are at most 10 non-matched nucleotides, e.g., there are 1, 2, 3, 4, 5 or 8 non-matched nucleotides.

[0060] As used herein, "stem-loop" structure is also named "hairpin" structure, referring to a type of nucleotide molecule that can form a secondary structure with a double-strand area (stem). The said double-strand area is formed by two parts of the nucleotide molecule (locating at the same molecule), and the said two parts are located respectively at two sides of the double-strand area; at least one "loop" structure is also included, which comprises non-complementary nucleotide molecules, i.e., the single-strand area. Even when the two parts of the nucleotide molecule is not completely complementary; the double-strand part thereof can keep the double-strand state. For example, insertion, absence, replacement in a small area can cause non-complement or formation of stem-loop structure or other kinds of secondary structures. However, the two areas can still complement with each other and react in a predictable manner, forming the double-strand area of the stem-loop structure. The stem-loop structure is commonly known by the skilled person in the art. Usually when being given a nucleic acid with nucleotide sequence of the first structure, a skilled person in the art can determine whether the nucleic acid can form the stem-loop structure.

[0061] The siRNAs disclosed in the present application refer to: micro RNAs of the BTK-inhibiting family, which include BTK-inhibiting siRNAs or modified BTK-inhibiting siRNA derivatives.

[0062] In one preferred example disclosed herein, the nucleotide sequence of the BTK-inhibiting siRNAs is shown as SEQ ID NO.: 1, 2 and 3. Most preferably is SEQ ID NO.: 3.

[0063] The present invention also includes siRNA variants and derivatives. Meanwhile, siRNA derivatives in the broader sense can also include siRNA variants. The ordinary skilled person in the art can modify the BTK-inhibiting siRNAs using conventional methods, including (but not being limited to): methylation modification, alkyl modification, glycosylation modification (such as 2-methoxy-glycosyl modification, alkyl-glycosyl modification, glycoconjugate modification and etc.), nucleination modification, peptide modification, lipid modification, nuclein modification (such as "TT" modification).

Polynucleotide construct



[0064] Basing on the siRNA sequence provided in the present invention, polynucleotide constructs can be designed, which can be processed into siRNAs that, being imported, can affect the expression of related mRNAs. Therefore, the present invention provides a type of isolated polynucleotide (construct), which can be transcribed in the human cell into precursor RNAs that can be cut in the human cell and expressed as the said siRNAs.

[0065] As one preferable embodiment of the present invention, the said polynucleotide construct comprises one or more structure units as shown in Formula II:

        Seqforward-X-Seqbackward     Formula II



[0066] In Formula II,
Seqforward is a nucleotide sequence that can be expressed in cells into the said BTK-inhibiting siRNA, Seqbackward is a nucleotide sequence that is substantially complementary with Seqforward; or, Seqbackward is the nucleotide sequence that can be expressed in cells into the said BTK-inhibiting siRNA, Seqforward is the nucleotide sequence that is substantially complementary with Seqbackward; X is a spacer sequence between Seqforward and Seqbackward. The said spacer sequence is complementary to neither Seqforward nor Seqbackward.

[0067] In which, each structure unit can express the same or different siRNAs;

[0068] Being transferred into cells, the structure shown in Formula I will form a secondary structure as shown in Formula III:



[0069] In Formula III, the Seqforward and Seqbackward and X are defined as above;
∥ represents the base complementary relationship between the Seqforward and Seqbackward;
The said polynucleotide construct is usually placed in an expression vector. Therefore, the present application also discloses an expression vector that contains the said siRNA or the said polynucleotide construct. The said expression vector usually comprises of a promoter, origin of replication and/or marker genes, and etc. Methods commonly known by the skilled persons in the art can be used to construct the expression vector needed in the present invention. These methods include DNA in vitro reconstruct, DNA synthesis and DNA in vivo reconstruct techniques, and etc. The said expression vector comprises preferably of one or several marker genes, such as resistance against kalamycin, gentamycin, hygromycin, ampicillin, so as to enable the selection of phenotypic characteristics of transformed host cells.

Bruton's agammaglobulinemia tyrosine kinase (Btk)



[0070] Bruton's agammaglobulinemia tyrosine kinase, Btk, is a member of the non-receptor tyrosine family. It comprises of 5 domains: the Pleckstr inhomology domaIn (PH domain), Tec homology domain (TH domain), Src homology3 domain (SH3 domain), Src homology2 domain (SH2 domain) and Tyrosine kinase domain (catalytic domain).

[0071] Tyrosine kinases can be classified according to their location in cells two kinds, receptor tyrosine kinases and non-receptor tyrosine kinases. The receptor tyrosine kinases locate on the cell membrane, being the receptor and enzyme at the same time. The non-receptor tyrosine kinases locate in the cytoplasma or nucleus. They are divided according to their homology into 11 families including Tec, AB 1 and Ack, and etc. Btk belongs to the Tec family of non-receptor tyrosine kinases. The domains can identify and combine with various signal molecules, providing structural foundation for the participation of Btk in multiple signal pathways.

[0072] The protein encoded by Btk is a cytoplasmic protein, so that the Btk protein is expressed by, except for T lymphocytes and phlogocytes from the development end of B lymphocytes, all other myeloid cells, including B lymphocytes, basophile granulocytes and monocytes, and etc., and is stably expressed during the whole development process of B lymphocytes. The survival and migration of malignant tumor cells mainly depends on the antigen receptor signal of B lymphocytes. In the signal pathway, Btk is an essential signal.

[0073] The amino acid and nucleotide sequence of human Btk is registered in Genbank under the number of NM_000061.

Pharmaceutical compositions



[0074] The present application discloses a pharmaceutical composition that comprises of a pharmaceutically acceptable carrier and one or several active ingredients disclosed herein with effective dose.

[0075] In another preferred example, the said modified siRNA derivative contains the monomer or the polymer of the compound with structure as shown in Formula I:

        (X)n-(Y)m     Formula I



[0076] In Formula I, each X is a siRNA said in (a); each Y is an independent modifier promoting the administration stability of small RNAs; n is a positive integer in 1-100 (preferably 1-20), (n is preferably 1, 2, 3, 4 or 5); m is a positive integer in 1-1000 (preferably 1-200); each "-" represents a connector, chemical bond or covalent bond; in another preferred example, the said connector is a nucleotide sequence with a length of 1-10 bases. The said Y includes (but is not limited to) cholesterol, steroid, sterol, alcohol, organic acid, aliphatic acid, ester, monosaccharide, polysaccharide, amino acid, polypeptide, mononucleotide, polynucleotide.

[0077] In another preferred example of the present invention, the polynucleotide said in (c) comprises one or several structure units as shown in Formula II:

        Seqforward-X-Seqbackward     Formula II



[0078] In Formula II, Seqforward is a nucleotide sequence that can be expressed in cells into the said BTK-inhibiting siRNA, Seqbackward is a nucleotide sequence that is substantially complementary with Seqforward; or, Seqbackward is the nucleotide sequence that can be expressed in cells into the said BTK-inhibiting siRNA, Seqforward is the nucleotide sequence that is substantially complementary with Seqbackward; X is a spacer sequence between Seqforward and Seqbackward. The said spacer sequence is complementary to neither Seqforward nor Seqbackward. And being transferred into the host cell, the structure shown in Formula II can transform into a secondary structure as shown in Formula III:



[0079] In Formula III, Seqforward, Seqbackward and X are defined as said above, ∥ represents the base complementary relationship between the Seqforward and Seqbackward;

[0080] In another preferred example of the present invention, the corresponding DNA sequence of encoding primer RNA is shown as SEQ ID NO. 7 and 4-6:



[0081] In which, the sequence of SEQ ID NO.: 7 is a polynucleotide sequence with tandem-connected BTK-1-2-3, in which:
The sequence of the polynucleotide relating to BTK-1 (i.e., DNA sequence that encodes the precursor RNA) is:



[0082] The sequence of the polynucleotide relating to BTK-2 (i.e., DNA sequence that encodes the precursor RNA) is:



[0083] The sequence of the polynucleotide relating to BTK-3 (i.e., DNA sequence that encodes the precursor RNA) is:



[0084] As used herein, the term "effective amount" or "effective dose" refers to the amount, with which a composition can take effect on and be accepted by humans and/or animals.

[0085] As used herein, "pharmaceutically acceptable" ingredient refers to an ingredient that is applicable on humans and/or mammals without excessive adverse side effects (such as toxicity, stimulation and allergic reaction), i.e., ingredient with sensible benefit/risk ratio. The term "pharmaceutically acceptable carrier" refers to the carrier for the effect ingredient, including all sorts of excipients and diluents.

[0086] The pharmaceutical composition of the present invention comprises the active ingredient of the present invention of the safe effect amount and a pharmaceutically acceptable carrier. The carriers include (but are not limited to): saline water, buffer, glucose, water, glycerol, ethanol, and a combination thereof. Generally, a pharmaceutical preparation shall match with the form of administration, and the dosage form of the pharmaceutical composition of the present invention can be injection, oral preparation (tablet, capsule, or oral liquid), transdermal agent, or sustained release agent. For example, preparation is performed with a conventional method using physiological saline or an aqueous solution containing glucose and other adjuvants. Said pharmaceutical composition is preferably produced under sterile conditions.

[0087] The effective amount of the active ingredient of the present invention may vary depending on the mode of administration and the severity of the disease to be treated. A person skilled in the art could determine the selection of the preferred effective amount depending on various factors (e.g., by clinical trials). Said factors include, but are not limited to, the pharmacokinetic parameters of said active ingredient, e.g., bioavailability, metabolism, half-life, etc.; and the severity of the patient's disease to be treated, the patient's weight, the patient's immune state, the administration route, etc. Generally, when the active ingredient of the present invention is administered at a dose of about 0.00001-50 mg/kg body weight (preferably 0.0001-10 mg/kg body weight) per day, satisfactory results can be achieved. For example, due to the urgent requirements of the treatment status, several separate doses can be administered on one day, or the dosage can be proportionally reduced.

[0088] In the present invention, the said pharmaceutically acceptable carriers include but are not limited to: water, saline solution, liposomes, lipids, proteins, protein-antibody complex, peptides, cellulose, nanogel, or the combination thereof. The choice of carriers should match the mode of administration, which is well known to an ordinary person skilled in the art.

[0089] The said active ingredient is used to prepare pharmaceutical compositions for the inhibition of BTKs, or the prevention or treatment of CLL.

Prevention or treatment method



[0090] The present application discloses a method to prevent or treat CLL.

[0091] In one preferred example, the said method includes administrating to subjects in need the pharmaceutical composition disclosed herein with safe and effective dose; or administrating the active ingredient disclosed herein with safe and effective dose.

[0092] The main advantages of the present application include:
  1. 1) Validates an essential type of siRNA sequences specific to BTK;
  2. 2) tandem-expresses BTK-specific siRNAs;
  3. 3) Provides a method to treat CLL targeting BTK, while validates that BTK-siRNA can be expressed in the cell using the generation mechanism of miRNAs.


[0093] The present invention is further illustrated in connection with particular embodiments as follows. It should be understood that these embodiments are merely illustrative of the invention and are not intended to limit the scope of the present invention. In the case of specific conditions for the experimental method being not specified in the following examples, generally conventional conditions are followed, such as the conditions described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbour Laboratory Press, 1989), or the conditions recommended by the manufacturer are followed. All percentages and portions are of weight unless otherwise indicated.

Example 1


Tandem-expression of BTK-specific siRNAs;


1. Experiment method


1.1 Construction of interference plasmid



[0094] In this example, 3 siRNAs are designed targeting the BTK gene, i.e., BTK-1, BTK-2 and BTK-3, of which the sequences are:

BTK-1: UUCACUGGACUCUUCACCUCU(SEQ ID NO.: 1);

BTK-2: UUAGCAGUUGCUCAGCCUGAC(SEQ ID NO.: 2);

BTK-3: AACAGUUUCGAGCUGCCAGGU(SEQ ID NO.: 3).



[0095] The expression precursors of the above-said 3 siRNAs are capsuled in the miRNA expression vector, so as to express the siRNAs in the form of miRNAs, constructing plasmids: P1, P2 and P3 respectively.

[0096] Meanwhile, 3 BTK siRNAs are tandem-expressed (comprising of 3 hairpin structures), so as to avoid adverse situations such as accidental off-target effect, constructing tandem-plasmid PI-2-3.

[0097] In which, the structure of polynucleotide sequence to express BTK-1, BTK-2, BTK-3 is shown as Figure 1, and the said sequence is shown as the following:





[0098] In which,

[0099] The sequence of the polynucleotide relating to BTK-1 is:



[0100] The sequence of the polynucleotide relating to BTK-2 is:



[0101] The sequence of the polynucleotide relating to BTK-3 is:


1.2 Cells



[0102] Peripheral blood of CLL patients and normal persons is extracted under sterile conditions and then given with anti-coagulants. Lymphocytes in the peripheral blood are isolated with lymphocyte separation solution on a super clean bench and then rinsed twice with PBS so as to leave the lymphocyte separation solution completely. The remaining red blood cells are lysated with red blood cell lysis buffer. The lymphocytes are finally re-suspended with RPMI-1640+15%FBS. Detecting with a flow cytometry determines that B lymphocytes take more than 95% of all. The cells from CLL patients are cultured at 37°C 5%CO2 for future use.

1.3 Transfection



[0103] Cells are processed 1 hour before transfection with exsuction and centrifugation, so as to remove the serum. After re-suspension with serum-free RPMI-1640, the cells are placed on a 12-hole plate and transfected with lipofection 2000 following the methods recommended by the instruction. After 48h of transfection, the cells are collected.

1.4 Extraction of RNA and synthesis of cDNA



[0104] Total RNA of cells is extracted with TRIzol reagent with the standard method, and then reverse-transcribed into cDNA using oligo dT primer and AMV transcriptase, and β-actin as internal reference.

1.5 Quantitative PCR detection



[0105] Quantitative PCR detection is performed with the primer of BTK and β-actin respectively.

BTK-P1: 5'-GAAGGAGGTTTCATTGTCA-3'(SEQ ID NO.: 8)

BTK-P2: 5'-TAATACTGGCTCTGAGGTGT-3' (SEQ ID NO.: 9)
Annealing temperature: 53°C.

ACT-P1:5'-CTCCATCCTGGCCTCGCTGT-3' (SEQ ID NO.: 10)

ACT-PI:5'- GCTGTCACCTTCACCGTTCC-3' (SEQ ID NO.: 11)
Annealing temperature: 52°C, product = 268bp.


1.6 Western blotting



[0106] Centrifugation at 1000rpm is performed for 5min, and then the cells are collected and lysated with cell lysis solution, followed by ice bath for 30min. Then cell debris is removed by centrifugation at 10000rpm for 10min. The extract total protein is then quantified, processed with 10% SDS-PAGE and then transferred on PVDV film, so as to be incubated with anti-BTK-specific antibodies. Enzyme-labeled rabbit anti-mouse second antibodies are added, and the protein is detected with the chemiluminescence method.

2. Results


2.1 detection of BTK mRNA expression change with QRT-PCR



[0107] 
Table 1
Control 1.0000
P1 0.7899
P2 0.7072
P3 0.5743
P1-2-3 0.4064


[0108] According to the results of QRT-PCR detection for BTK mRNA expression (as shown in Table 1 and Figure 2), it can be told that plasmid P1, P2, P3 and P1-2-3 are all effective, while P1-2-3 is the most effective.

[0109] It is proved that single siRNA or multiple siRNAs can inhibit the expression of BTK, in which these in the form of tandem-expression functions at the best, followed by BTK-3.

2.2 Detection of BTK protein expression change with Western blotting



[0110] As shown in Figure 3, BTK expression in the CLL patients is significantly higher than that of the normal persons,

2.3 Western blotting validates that a single siRNA or multiple siRNAs can inhibit the expression of BTK.



[0111] The detection result of BTK protein expression with Western blotting is as shown in Figure 4. The results also indicate that plasmids P1, P2, P3 and P1-2-3 (tandem-expression of the three) are all effective in BTK inhibition.

Example 2 Effect of BTK siRNA on B lymphocytes


1.1 Preparation of B lymphocytes



[0112] In this example, normal Daudi cells (lymphocytes) are resuscitated, cultured with RPMI-1640+10%FBS, at 37°C 5% CO2 for future use.

1.2 Transfection



[0113] The method is as said in part 1.3 of Example 1.

1.3 Extraction of RNA and synthesis of cDNA



[0114] The method is as said in part 1.4 of Example 1.

[0115] Figure 1.4 Analysis with the Western blotting method on the effect of BTK siRNA on BTK protein.

[0116] The method is as said in part 1.6 of Example 1.

[0117] The detailed results are shown in Fig. 5 and 6. After the transfection of plasmid-1, plasmid-2, plasmid-3 and plasmid-1-2-3 (tandem of 3 plasmids), the expression of BTK protein reduces, indicating that all of plasmid-1, plasmid-2, plasmid-3 and plasmid-1-2-3 can effectively inhibit BTK, in which the plasmid-1-2-3 in the form of tandem expression is significantly more effective, down-regulating the expression of BTK protein at around 50%, followed by plasmid-2.

1.5 Detection for the effect of BTK siRNA on BTK mRNA with QRT-PCR



[0118] Quantitative PCR detection is performed with the primer of BTK and β-actin respectively. The method is as said in part 1.5 of Example 1, but with different primers shown as follows:

BTK primer F15:5'-TGCTCCCACTCAATACAAA-3' (SEQ ID NO.: 12)

BTK primer R15'-GCTCTACCAAATGCCTACTC-3'(SEQ ID NO.: 13)
Annealing temperature: 53°C.

ACT-P1:5'-CTCCATCCTGGCCTCGCTGT-3'(SEQ ID NO.: 10)

ACT-P1:5'- GCTGTCACCTTCACCGTTCC-3'(SEQ ID NO.: 11)
Annealing temperature: 52°C, product = 268bp.



[0119] The detailed results are shown in Figure 7, 8, 9, 10.

[0120] It can be seen in Figure 7 that, being compared with transfection of blank plasmid (plasmid nc), the expression of BTK-1 in B lymphocytes is significantly increased with transfection of P1, P1-2-3.

[0121] It can be seen in Figure 8 that, being compared with transfection of blank plasmid (plasmid nc), the expression of BTK-2 in B lymphocytes is significantly increased with transfection of P2, P1-2-3.

[0122] It can be seen in Figure 9 that, being compared with transfection of blank plasmid (plasmid nc), the expression of BTK-3 in B lymphocytes is significantly increased with transfection of P3, P1-2-3.

[0123] It can be seen in Figure 10 that, with transfection of P1, P2, P3 and P1-2-3 (tandem of 3 plasmids), the expression of BTK mRNA is reduced, indicating that all of P1, P2, P3 and P1-2-3 can effectively inhibit BTK mRNA. Being compared with the control group, the tandem-expression of PI-2-3 is more effective, with the BTK mRNA reduced at around 50%.

[0124] In summary, being transfected with BTK siRNA plasmids P1, P2, P3 and PI-2-3, the expression of BTK-1, BTK-2 and BTK-3 siRNA is all increased; the expression of BTK mRNA and BTK protein is decreased. All of BTK-1, BTK-2, BTK-3 and tandem-expressed PI-2-3 can inhibit the BTK gene and protein in B lymphocytes. And the inhibition on the BTK gene and protein in B lymphocytes of the tandem-expressed PI-2-3 is stronger and with better effect.

Sequence listing



[0125] 

<110> JIANGSU MICROMEDMARK BIOTECH CO., LTD.

<120> SIRNA IN TANDEM EXPRESSION AND USES THEREOF IN TREATING CHRONIC
LYMPHOCYTIC LEUKEMIA

<130> P2014-1568

<150> CN 201410043517.9
<151> 2014-01-29

<160> 13

<170> PatentIn version 3.5

<210> 1
<211> 21
<212> RNA
<213> Artificial sequence

<220>
<223> siRNA

<400> 1
uucacuggac ucuucaccuc u 21

<210> 2
<211> 21
<212> RNA
<213> Artificial sequence

<220>
<223> siRNA

<400> 2
uuagcaguug cucagccuga c 21

<210> 3
<211> 21
<212> RNA
<213> Artificial sequence

<220>
<223> siRNA

<400> 3
aacaguuucg agcugccagg u 21

<210> 4
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> the DNA sequence for encoding precursor RNA

<400> 4
ttcactggac tcttcacctc tgttttggcc actgactgac agaggtgaag tccagtgaa 59

<210> 5
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> the DNA sequence for encoding precursor RNA

<400> 5
ttagcagttg ctcagcctga cgttttggcc actgactgac gtcaggctgc aactgctaa 59

<210> 6
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> the DNA sequence for encoding precursor RNA

<400> 6
aacagtttcg agctgccagg tgttttggcc actgactgac acctggcatc gaaactgtt 59

<210> 7
<211> 334
<212> DNA
<213> Artificial sequence

<220>
<223> polynucleotide sequence formed by BTK-1-2-3 in tandem

<400> 7

<210> 8
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> primer

<400> 8
gaaggaggtt tcattgtca 19

<210> 9
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> primer

<400> 9
taatactggc tctgaggtgt 20

<210> 10
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> primer

<400> 10
ctccatcctg gcctcgctgt 20

<210> 11
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> primer

<400> 11
gctgtcacct tcaccgttcc 20

<210> 12
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> primer

<400> 12
tgctcccact caatacaaa 19

<210> 13
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> primer

<400> 13
gctctaccaa atgcctactc 20




Claims

1. A recombinant polynucleotide for inhibiting Bruton's agammaglobulinemia tyrosine kinase (BTK), wherein the nucleotide sequence of the polynucleotide has a structure of Formula V:

        A-(B-L-)p-Z     (V)

wherein,

A represents an optional sequence at 5' end (preferably, the length thereof is 0-50bp, more preferably, 0-20bp, and most preferably, 0-10bp);

B represents a same or different siRNA sequence that specifically inhibits BTK, or a precursor RNA sequence used to produce the siRNA sequence, wherein the siRNA sequence includes a siRNA as shown in SEQ ID NO.: 2;

L represents an optional interval sequence (preferably, the length thereof is 0-50bp, more preferably, 0-20bp, and most preferably, 0-10bp);

p is a positive integer of 1, 2, 3, 4 or 5;

Z represents an optional sequence at 3' end (preferably, the length thereof is 0-50bp, more preferably, 0-20bp, and most preferably, 0-10bp);


 
2. The polynucleotide of claim 1, which comprises DNA and RNA sequences.
 
3. The polynucleotide of claim 1, whose sequence is a tandem nucleotide sequence that expresses 2 or more different siRNA sequences.
 
4. The polynucleotide of claim 3, whose sequence is a tandem nucleotide sequence that expresses three siRNAs as shown in SEQ ID NO.: 1, 2 and 3.
 
5. The polynucleotide of claim 1, wherein B is a precursor RNA for producing the siRNA and the precursor RNA sequence is as shown in SEQ ID NO.:7.
 
6. A pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and an effective amount of one or more active ingredients selected from the group consisting of:

(a) a BTK inhibiting siRNA, wherein the siRNA includes a siRNA as shown in SEQ ID NO.: 2;

(b) a precursor RNA, which can be processed in the host into the BTK inhibiting-siRNA of (a);

(c) a polynucleotide, which can be transcribed in the host into the precursor RNA of (b), and then processed into the siRNA of (a); and

(d) an expression vector, which contains the BTK inhibiting siRNA of (a), or the precursor RNA of (b), or the polynucleotide of (c).


 
7. The composition of claim 6, wherein the polynucleotide of (c) expresses 2 or more different siRNA sequences in tandem.
 
8. The composition of claim 6, wherein the polynucleotide of (c) comprises one or more structure units as shown in Formula II:

        Seqforward-X-Seqbackward     II

wherein,

Seqforward is a nucleotide sequence that can be processed into a microRNA in the host;

Seqbackward is a nucleotide sequence essentially or completely complementary to the Seqforward;

X is an interval sequence between Seqforward and Seqbackward, and the interval sequence is not complementary to any of Seqforward and Seqbackward;

and after being transferred into the host cell, the structure of Formula II forms a secondary structure as shown in Formula III:

wherein, Seqforward and Seqbackward and X are defined as above;

∥ indicates a complementary base pairing relationship between Seqforward and Seqbackward; and

the Seqforward in each construct unit can be the same or different.


 
9. The composition of claim 6, wherein active ingredient is a tandem nucleotide sequence that expresses three siRNAs as shown in SEQ ID NO.: 1, 2 and 3.
 
10. The composition of claim 6, wherein the active ingredient is a precursor RNA as shown in SEQ ID NO.:7.
 
11. An active ingredient for use for the inhibition of BTKs, or the prevention or treatment of CLL, wherein, the active ingredient is selected from the group consisting of :

(a) a BTK inhibiting siRNA, wherein the siRNA includes a siRNA as shown in SEQ ID NO.: 2;

(b) a precursor RNA, which can be processed in the host into the BTK inhibiting siRNA of (a);

(c) a polynucleotide, which can be transcribed in the host into the precursor RNAs of (b), and then processed into the siRNA of (a); and

(d) an expression vector, which contains the BTK inhibiting siRNA of (a), or the precursor RNA of (b), or the polynucleotide of (c).


 
12. The active ingredient for use according to claim 11, wherein the active ingredient is the polynucleotide of (c) and the polynucleotide simultaneously expresses three siRNA shown in SEQ ID NO.: 1, 2 and 3 in tandem.
 
13. The active ingredient for use according to claim 11, wherein the active ingredient is a precursor RNA as shown in SEQ ID NO.:7.
 


Ansprüche

1. Rekombinantes Polynukleotid zur Hemmung von Bruton's Agammaglobulinämie Tyrosinkinase (BTK), wobei die Nukleotidsequenz des Polynukleotids eine Struktur nach Formel V aufweist:

        A-(B-L-)p-Z     (V)

wobei

A eine optionale Sequenz am 5'-Ende darstellt (vorzugsweise beträgt deren Länge 0-50 bp, insbesondere 0 - 20 bp und besonders bevorzugt 0-10 bp);

B eine gleiche oder unterschiedliche siRNA-Sequenz, die BTK spezifisch hemmt, oder eine Präkursor-RNA-Sequenz, die zur Erzeugung der siRNA-Sequenz verwendet wird, darstellt, wobei die siRNA-Sequenz eine siRNA nach SEQ ID NO: 2 umfasst;

L eine optionale Intervallsequenz darstellt (vorzugsweise beträgt deren Länge 0 - 50 bp, insbesondere 0 - 20 bp und besonders bevorzugt 0-10 bp);

p eine positive Ganzzahl gleich 1, 2, 3, 4 oder 5 ist;

Z eine optionale Sequenz am 3'-Ende darstellt (vorzugsweise beträgt deren Länge 0-50 bp, insbesondere 0 - 20 bp und besonders bevorzugt 0-10 bp).


 
2. Polynukleotid nach Anspruch 1, welches DNA- und RNA-Sequenzen umfasst.
 
3. Polynukleotid nach Anspruch 1, dessen Sequenz eine Tandem-Nukleotidsequenz ist, die 2 oder mehr unterschiedliche siRNA-Sequenzen exprimiert.
 
4. Polynukleotid nach Anspruch 3, dessen Sequenz eine Tandem-Nukleotidsequenz ist, die drei siRNAs nach SEQ ID NO: 1, 2 und 3 exprimiert.
 
5. Polynukleotid nach Anspruch 1, wobei B eine Präkursor-RNA zur Erzeugung der siRNA ist und die Präkursor-RNA-Sequenz in SEQ ID NO: 7 dargestellt ist.
 
6. Pharmazeutische Zusammensetzung, umfassend einen pharmazeutisch unbedenklichen Träger und eine wirksame Menge an mindestens einem aus folgender Gruppe gewählten Wirkstoff:

(a) eine BTK hemmende siRNA, wobei die siRNA eine siRNA nach SEQ ID NO: 2 umfasst;

(b) eine Präkursor-RNA, die beim Wirt zur BTK hemmenden siRNA nach (a) verarbeitet werden kann;

(c) ein Polynukleotid, das sich beim Wirt in die Präkursor-RNA nach (b) transkribieren und anschließend zur siRNA nach (a) verarbeiten lässt, und

(d) ein Expressionsvektor, der die BTK hemmende siRNA nach (a), die Präkursor-RNA nach (b) oder die Polynukleotid nach (c) enthält.


 
7. Zusammensetzung nach Anspruch 6, wobei das Polynukleotid nach (c) 2 oder mehr unterschiedliche siRNA-Sequenzen zusammen exprimiert.
 
8. Zusammensetzung nach Anspruch 6, wobei das Polynukleotid nach (c) mindestens eine Struktureinheit der Formel II umfasst:

        Seqvorwärts-X-Seqrückwärts     II

wobei

Seqvorwärts eine Nukleotidsequenz ist, die sich beim Wirt zu einer microRNA verarbeiten lässt;

Seqrückwärts eine Nukleotidsequenz, die der Seqforward im Wesentlichen oder völlig komplementär ist;

X eine Intervallsequenz zwischen Seqvorwärts und Seqrückwärts ist und die Intervallsequenz weder Seqvorwärts noch Seqrückwärts komplementär ist;

und die Struktur der Formel II nach der Übertragung in die Wirtszelle eine sekundäre Struktur der Formel III bildet:

wobei Seqvorwarts, Seqrückwärts und X der obigen Definition entsprechen;

∥ eine komplementäre Basenpaarbeziehung zwischen Seqvorwärts und Seqrückwärts kennzeichnet; und

die Seqvorwärts in jeder Konstrukteinheit gleich oder unterschiedlich sein kann.


 
9. Zusammensetzung nach Anspruch 6, wobei ein Wirkstoff eine Tandem-Nukleotidsequenz ist, die drei siRNAs nach SEQ ID NO: 1, 2 und 3 exprimiert.
 
10. Zusammensetzung nach Anspruch 6, wobei der Wirkstoff eine Präkursor-RNA der SEQ ID NO: 7 ist.
 
11. Wirkstoff zur Verwendung zur Hemmung von BTKs oder zur Verhütung bzw. Behandlung von CLL, wobei der Wirkstoff aus folgender Gruppe gewählt ist:

(a) eine BTK hemmende siRNA, wobei die siRNA eine siRNA nach SEQ ID NO: 2 umfasst;

(b) eine Präkursor-RNA, die beim Wirt zur BTK hemmenden siRNA nach (a) verarbeitet werden kann;

(c) ein Polynukleotid, das sich beim Wirt in die Präkursor-RNAs nach (b) transkribieren und anschließend zur siRNA nach (a) verarbeiten lässt, und

(d) ein Expressionsvektor, der die BTK hemmende siRNA nach (a), die Präkursor-RNA nach (b) oder die Polynukleotid nach (c) enthält.


 
12. Wirkstoff zur Verwendung nach Anspruch 11, wobei der Wirkstoff das Polynukleotid nach (c) ist und das Polynukleotid gleichzeitig drei siRNAs nach SEQ ID NO: 1, 2 und 3 zusammen exprimiert.
 
13. Wirkstoff zur Verwendung nach anspruch 11, wobei der Wirkstoff eine Präkursor-RNA nach SEQ ID NO: 7 ist.
 


Revendications

1. Polynucléotide recombinant pour inhiber la tyrosine kinase de l'agammaglobulinémie de Bruton (BTK), où la séquence de nucléotides du polynucléotide possède une structure de Formule V :

        A-(B-L-)p-Z     (V)

dans laquelle,

A représente une séquence facultative à l'extrémité 5' (de préférence, la longueur de celle-ci est de 0-50 pb, de manière davantage préférée, 0-20 pb, et de la manière la plus préférée entre toutes, 0-10 pb) ;

B représente une séquence d'ARNsi identique ou différente qui inhibe spécifiquement la BTK, ou une séquence d'ARN précurseur utilisée pour produire la séquence d'ARNsi, où la séquence d'ARNsi comprend un ARNsi tel que montré dans SEQ ID NO: 2 ;

L représente une séquence d'intervalle facultative (de préférence, la longueur de celle-ci est de 0-50 pb, de manière davantage préférée, 0-20 pb, et de la manière la plus préférée entre toutes, 0-10 pb) ;

p est un nombre entier positif de 1, 2, 3, 4 ou 5 ;

Z représente une séquence facultative à l'extrémité 3' (de préférence, la longueur de celle-ci est de 0-50 pb, de manière davantage préférée, 0-20 pb, et de la manière la plus préférée entre toutes, 0-10 pb).


 
2. Polynucléotide selon la revendication 1, qui comprend des séquences d'ADN et d'ARN.
 
3. Polynucléotide selon la revendication 1, dont la séquence est une séquence de nucléotides en tandem qui exprime 2 séquences d'ARNsi différentes ou plus.
 
4. Polynucléotide selon la revendication 3, dont la séquence est une séquence de nucléotides en tandem qui exprime trois ARNsi tels que montrés dans SEQ ID NO: 1, 2 et 3.
 
5. Polynucléotide selon la revendication 1, dans lequel B est un ARN précurseur pour produire l'ARNsi et la séquence de l'ARN précurseur est telle que montrée dans SEQ ID NO: 7.
 
6. Composition pharmaceutique, qui comprend un véhicule pharmaceutiquement acceptable et une quantité efficace d'un ou de plusieurs ingrédients actifs sélectionnés dans le groupe consistant en :

(a) un ARNsi inhibant la BTK, où l'ARNsi comprend un ARNsi tel que montré dans SEQ ID NO: 2 ;

(b) un ARN précurseur, qui peut être transformé chez l'hôte en l'ARNsi inhibant la BTK de (a) ;

(c) un polynucléotide, qui peut être transcrit chez l'hôte en l'ARN précurseur de (b), puis être transformé en l'ARNsi de (a) ; et

(d) un vecteur d'expression, qui contient l'ARNsi inhibant la BTK de (a), ou l'ARN précurseur de (b), ou le polynucléotide de (c).


 
7. Composition selon la revendication 6, dans laquelle le polynucléotide de (c) exprime 2 séquences d'ARNsi différentes ou plus en tandem.
 
8. Composition selon la revendication 6, dans laquelle le polynucléotide de (c) comprend une ou plusieurs unités de structure telles que montrées dans la Formule II :

        Seqsens-X-Seqantisens     II

dans laquelle,

Seqsens est une séquence de nucléotides qui peut être transformée en un microARN chez l'hôte ;

Seqantisens est une séquence de nucléotides essentiellement ou totalement complémentaire à la Seqsens ;

X est une séquence d'intervalle entre Seqsens et Seqantisens, et la séquence d'intervalle n'est pas complémentaire à l'une quelconque de Seqsens et Seqantisens ;

et après avoir été transférée dans la cellule hôte, la structure de Formule II forme une structure secondaire telle que montrée dans la Formule III :

dans laquelle, Seqsens et Seqantisens et X sont définis tel que ci-dessus ;

Il indique une relation d'appariement de bases complémentaires entre Seqsens et Seqantisens ; et

la Seqsens dans chaque unité de construction peut être identique ou différente.


 
9. Composition selon la revendication 6, dans laquelle l'ingrédient actif est une séquence de nucléotides en tandem qui exprime trois ARNsi tels que montrés dans SEQ ID NO: 1, 2 et 3.
 
10. Composition selon la revendication 6, dans laquelle l'ingrédient actif est un ARN précurseur tel que montré dans SEQ ID NO: 7.
 
11. Ingrédient actif destiné à être utilisé pour l'inhibition de BTK, ou la prévention ou le traitement de la LLC, où l'ingrédient actif est sélectionné dans le groupe consistant en :

(a) un ARNsi inhibant la BTK, où l'ARNsi comprend un ARNsi tel que montré dans SEQ ID NO: 2 ;

(b) un ARN précurseur, qui peut être transformé chez l'hôte en l'ARNsi inhibant la BTK de (a) ;

(c) un polynucléotide, qui peut être transcrit chez l'hôte en les ARN précurseurs de (b), puis être transformé en l'ARNsi de (a) ; et

(d) un vecteur d'expression, qui contient l'ARNsi inhibant la BTK de (a), ou l'ARN précurseur de (b), ou le polynucléotide de (c).


 
12. Ingrédient actif destiné à être utilisé selon la revendication 11, où l'ingrédient actif est le polynucléotide de (c) et le polynucléotide exprime simultanément trois ARNsi montrés dans SEQ ID NO: 1, 2 et 3 en tandem.
 
13. Ingrédient actif destiné à être utilisé selon la revendication 11, où l'ingrédient actif est un ARN précurseur tel que montré dans SEQ ID NO: 7.
 




Drawing















REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description